Title of article :
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Author/Authors :
Shumpei Yokota، نويسنده , , Tomoyuki Imagawa، نويسنده , , Masaaki Mori، نويسنده , , Takako Miyamae، نويسنده , , Yukoh Aihara، نويسنده , , Shuji Takei، نويسنده , , Naomi Iwata، نويسنده , , Hiroaki Umebayashi، نويسنده , , Takuji Murata، نويسنده , , Mari Miyoshi، نويسنده , , Minako Tomiita، نويسنده , , Norihiro Nishimoto، نويسنده , , Tadamitsu Kishimoto، نويسنده ,
Abstract :
Background
Systemic-onset juvenile idiopathic arthritis does not always respond to available treatments, including antitumour necrosis factor agents. We investigated the efficacy and safety of tocilizumab, an anti-interleukin-6-receptor monoclonal antibod
